Medical aesthetic corporations VAIM laid the groundwork to enter the Chinese market with its flagship skin booster "Juvelook (JUVELOOK)."
VAIM said on the 3rd that Juvelook obtained Class III medical device approval from China's National Medical Products Administration (NMPA).
With this approval, the company opened the door to the Chinese market, considered the world's largest aesthetic medicine market along with the United States.
According to the company, Juvelook is a skin booster that combines the biodegradable polymer PDLLA with hyaluronic acid (HA), promoting collagen and elastin production in the skin to help improve elasticity and skin texture. The company said it also secured a Chinese patent for its core technology, a "porous reticular structure" in which tiny holes are connected like a mesh.
VAIM plans to target the market starting in the second half by conducting procedure training and academic seminars for local Chinese medical professionals. It has signed exclusive sales contracts with about 80 countries, and cumulative production of Juvelook has surpassed 3 million vials.
VAIM CEO Park Jong-hyeon said, "China is a market with both high regulatory standards and strong potential," adding, "We will secure trust from local medical professionals and consumers based on academic evidence, and target the Chinese market by focusing on standardizing procedure protocols and training medical professionals."